Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Biocon Pumps Up For Adalimumab US Debut Amid Payer ‘Steady State’

Biocon is confident of its “four channel strategy” for the upcoming debut of biosimilar Humira in the US and also asserts it’s well positioned to compete when price cuts come into play for Sanofi’s Lantus next year.

Sales & Earnings Commercial

Glucagon And Epinephrine Continue To Drive Growth At Amphastar

Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.

Sales & Earnings Generic Drugs

Teva Is Committed To Alvotech Alliance – But Would ‘Love’ To Move On Adalimumab ‘Soon’

Teva has spoken of its US biosimilars alliance with Alvotech, in the wake of several major setbacks for the companies’ plans to launch a biosimilar to AbbVie’s Humira (adalimumab) juggernaut on 1 July.

Biosimilars Complete Response Letters

Cipla's Advair Generic US Debut May Be Pushed Out But 'Value Intact'

Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.

Sales & Earnings Strategy

Fresenius Brings In Transparency Change For Kabi Unit

Fresenius Kabi has switched from a geographic to segment-focused quarterly disclosure, in an attempt to improve transparency across its four key business units, three of which have been identified as key growth drivers.

Sales & Earnings Strategy

Lupin's Generic Spiriva Launch Delayed As FDA Action Expected By August

Lupin has pushed the US launch for a generic to Boehringer’s blockbuster COPD drug Spiriva to September as FDA action is now expected “latest by August”. Meanwhile, an acquisition of Medisol in France and ANDA submissions in the US are part of an ongoing focus on injectables.

Strategy Launches

Viatris Is ‘Not Walking Away’ From Generics

After reporting sliding sales for both generics and complex generics in Q1, Viatris has nevertheless reaffirmed its commitment to the off-patent sector, highlighting in particular a planned launch this year of its Breyna rival to Symbicort.

Strategy Sales & Earnings

Francis Takes Stock Of Teva Ahead Of Revealing Fresh Strategy

As Teva prepares to unveil a fresh strategy under new CEO Richard Francis on 18 May, the company has delivered Q1 results along with an update on planned US launches for long-acting injectable risperidone as well as biosimilar adalimumab.

Sales & Earnings Strategy

ANI Revises Its Expectations Up Following Record Revenues

ANI has revised up its annual expectations in the face of an outstanding first quarter, which saw it beat market expectations by a substantial margin.

Sales & Earnings Strategy
UsernamePublicRestriction

Register